CollabRx and GeneInsight to Collaborate on Interpretation and Reporting Service for Clinical Genetic Sequencing

May 8, 2013

San Francisco, CA and Boston, MA, May 8, 2013 (GLOBE NEWSWIRE) – CollabRx, Inc. (NASDAQ: CLRX), a data analytics company focused on informing the clinical interpretation of molecular diagnostic testing, and GeneInsight LLC., a leading developer of software to support knowledge management and reporting for genetic testing laboratories, today announced an agreement to deliver a unique medical informatics solution to support the interpretation and reporting of genetic variants from sequencing-based tests. 

CollabRx and GeneInsight maintain that their joint initiative is designed to establish a robust medical informatics solution to support genetic sequencing, interpretation, and reporting in the clinical laboratory. GeneInsight has been in use since 2005 and has supported the interpretation and reporting workflow for more than 30,000 clinical genetic tests across multiple diagnostic reference laboratories.   Under terms of the agreement, CollabRx medical and scientific content will be made accessible through the GeneInsight knowledge management platform.  Initially focused on oncology, the combined offering will be available to the clinical laboratory market. 

“We are excited to work with GeneInsight to provide a key medical informatics capability to the genetic testing laboratory market to accelerate adoption of next generation sequencing-based tests for cancer and beyond,” said Thomas R. Mika, CollabRx Chairman, President and Chief Executive Officer.  “Our partnership with GeneInsight goes a long way towards enabling a truly integrated clinical laboratory workflow.”

Organizing and clinically interpreting genetic sequence data is among the greatest challenges facing treating clinicians. The massive amount of information is overwhelming physicians and limits their ability to utilize genetic information to inform routine patient care, particularly for oncology.  The combined offering in oncology will enable clinical laboratories to catalogue genetic variants from sequencing-based tests, and associate them with CollabRx’s expertly curated knowledge on available drugs and clinical trials.  Laboratories will have the option to incorporate this information into reports for treating physicians to enable increasingly informed treatment planning. Knowledge management, reporting and delivery of findings to ordering clinicians will be streamlined through GeneInsight’s networked infrastructure, providing clinical laboratories the means to update physicians as knowledge evolves so they can effectively manage patient care.

“The CollabRx and GeneInsight collaboration will enable laboratories using GeneInsight to leverage CollabRx content as they draft reports explaining the significance of variants identified in patients,” said Heidi Rehm, PhD, Chief Laboratory Director, Partners’ Laboratory for Molecular Medicine. “When it comes to diagnosing and developing treatments, we work closely with scientists and clinicians at Massachusetts General Hospital and Brigham and Women’s Hospital to advance patient care. We are thrilled to work with CollabRx and its more than 75 leading independent clinical practitioners to accelerate adoption of clinical sequencing in cancer.”

About CollabRx

CollabRx, Inc. (NASDAQ: CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.

About GeneInsight

GeneInsight, LLC is a wholly-owned subsidiary of Partners HealthCare.  GeneInsight Suite® was developed by Partners HealthCare in collaboration with leading geneticists, laboratory operations personnel, practicing physicians and IT professionals. GeneInsight has been in clinical use since 2005 and has supported the interpretation and reporting workflow for more than 30,000 clinical genetic tests across multiple diagnostic reference laboratories, including the Partners HealthCare Laboratory for Molecular Medicine.  More information can be obtained at http://www.geneinsight.com.

About Partners HealthCare

Partners HealthCare is an integrated health system founded by Brigham and Women’s Hospital and Massachusetts General Hospital.  In addition to its two academic medical centers, the Partners system includes community and specialty hospitals, a managed care organization, community health centers, a physician network, home health and long-term care services, and other health-related entities.  Partners is one of the nation’s leading biomedical research organizations and a principal teaching affiliate of Harvard Medical School.  Partners HealthCare is a non-profit organization.

CollabRx Safe Harbor Statement

This press release includes forward-looking statements about CollabRx’s anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx’s plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

CollabRx Contacts:
Thomas R. Mika, CEO
CollabRx, Inc.
415-248-5350

Robert Ferri Partners, LLC:
Robert Ferri
(415) 575-1589 (direct)
robert.ferri@robertferri.com

Partners Healthcare Contact:
Rich Copp
617-278-1031
Rcopp@partners.org